Longeveron (LGVN) Cost of Revenue (2020 - 2026)
Longeveron (LGVN) recorded quarterly Cost of Revenue of $134000.0 in Q1 2026, up 24.07% quarter-over-quarter from $108000.0 in Q4 2025, and up 26.42% on a YoY basis from $106000.0 in Q1 2025.
Longeveron (LGVN) Cost of Revenue (2020 - 2026) Analysis & Trends
Longeveron's Cost of Revenue history runs 7 years deep, the most recent figure standing at $134000.0 for Q1 2026.
- In Q1 2026, Cost of Revenue rose 26.42% year-over-year to $134000.0; the TTM figure through Mar 2026 stood at $424000.0 (up 7.61% YoY), while the FY2025 annual figure was $396000.0, down 22.05% from the prior year.
- Cost of Revenue was $134000.0 for Q1 2026 at Longeveron, up from $108000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $502000.0 in Q4 2022 to a low of $12000.0 in Q3 2025.
- Historically, Cost of Revenue has averaged $155235.3 across 5 years, with a median of $124000.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 341.51% in 2022, then tumbled 87.05% in 2023.
- A 5-year view of Cost of Revenue shows it stood at $502000.0 in 2022, then sank by 87.05% to $65000.0 in 2023, then rose by 12.31% to $73000.0 in 2024, then soared by 47.95% to $108000.0 in 2025, then increased by 24.07% to $134000.0 in 2026.
- The last three Cost of Revenue figures came in at $134000.0 (Q1 2026), $108000.0 (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Dec 31, 2023 | 65,000.00 |
| Dec 31, 2023 | 65,000.00 |